Get all premium features to the best stock analysis tool

C3 AI Announces Preliminary Fourth Quarter and Full Fiscal Year 2026 Results; Thomas M. Siebel Resumes Role of Chief Executive Officer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--C3.ai, Inc. (“C3 AI,” “C3,” or the “Company”) (NYSE: AI), the Enterprise AI application software company, today announced preliminary financial results for its fourth quarter and full fiscal year ended April 30, 2026, and significant changes to its executive leadership. Leadership Update Effective May 8, 2026, Thomas M. Siebel resumed the role of Chief Executive Officer of C3 AI and continues to serve as Chairman of the Board of Directors. Stephen Ehikian.

Global Engine Group Holding Limited and Angkasa-X Holdings Corp. Enter Into Memorandum of Understanding to Explore Integration of Satellite Networks, Data Infrastructure, and Blockchain Technology to Support Artificial Intelligence (AI) Applications

HONG KONG, May 06, 2026 (GLOBE NEWSWIRE) -- Global Engine Group Holding Limited (Nasdaq: GLE) (the “Company” or “GLE”), a Hong Kong-headquartered integrated solutions provider in information communication technologies (“ICT”), today announced its entry into a non-binding strategic memorandum of understanding (“MOU”) with Angkasa-X Holdings Corp. (“Angkasa-X”), a satellite technology company specializing in Low Earth Orbit (“LEO”) satellite constellations and satellite-based data services, to develop a fully integrated Space-to-AI digital infrastructure platform. This collaboration is intended to integrate satellite services, global data infrastructure, and blockchain technology to power the evolving AI economy.

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's platform, which leverages cutting-edge AI agent technology, is built to interrogate large biological datasets in a fraction of the time and cost of traditional methods.